may repeat may-june trend..

keep uptrend ..

wa good eh!!

any good news..?

today ptaras ..

buy..

buy

keep..

buy

bonus 1:1 11.12.2024 ex

buy

buy

superb QR

good company

https://theedgemalaysia.com/node/732598 seed oil free cert

swk good div .. taann will follow

swk good too

good QR3

just keep ..

the last QR/Q4 will be very good too

this QR is going to be v good

buy..

https://www.youtube.com/watch?v=1W4GtYDKiMI&t=4s

https://www.seedoilfreecertified.com/overview/

https://www.seedoilfreecertified.com/overview/

yes!

good production of ffb, buy swk..

above 3 b4 bonus issue ex ..

buy

Ts last bonus issue was Jan2015 1:2

y must sell😁

teoseng

no news of removal in budget 2025 is good news for chicken eggs

Given the economies of scale and its integrated business model, Chew(Lhi CFO) believes Lhi and its subsidiary Teoseng will be well shielded from any adverse effects (removal of subsidy for chicken eggs). --The Edge 14.10.2024

Given the economies of scale and its integrated business model, Chew(Lhi CFO) believes Lhi and its subsidiary Teoseng will be well shielded from any adverse effects (removal of subsidy for chicken eggs). --The Edge 14.10.2024

buy

When both property development and hospitality pull their weight
and contribute to the bottom line, I would expect significant
improvement to the return. The profitability picture as well as its
strong financial position suggest that Plenitude is not a value trap. --Dato Eu

teoseng's day coming after cck ..

n div is increasing..

good eggs producer with high roe n low pe

buy deleum n penergy..

deleum moving..

For the first half of 2023, the Group recorded a profit before tax of RM31.3 million compared to RM24.4 million in the same period last year mainly due to higher sales
from domestic and overseas market and foreign exchange gain resulted from weakening of the Ringgit against the US Dollar.
--Q2 2023😁

fundamental will support share price at around 2.50 b4 next Q...

https://klse.i3investor.com/web/pricetarget/research/72055

buy more ..

buy more ..

syg pb 0.79 harbour pb0.8 fair

upup

https://www.ctee.com.tw/news/20220714700772-439801
永信東南亞控股是台灣本土學名藥製藥廠中，第一家跨國上市的公司。這兩年，受疫情影響，年營收成長仍有3％〜5％。即將來臨的後疫情時代，李芳信預計，自2022年起，公司營收至少有雙位數以上的成長。